Table 3 Multivariable analysis for overall survival in localized pancreatic cancer patients.
From: Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis
Parameter | Hazard ratio | 95% CI limits | p value | |
|---|---|---|---|---|
Sex male vs. female (ref. male) | 0.88 | 0.45 | 1.72 | 0.72 |
Neoadjuvant treatment (y/n) (Ref. yes) | 0.77 | 0.37 | 1.52 | 0.47 |
Stage I vs. II (Ref. Stage I) | 1.60 | 0.59 | 4.90 | 0.32 |
Borderline disease (y/n) (Ref. no) | 1.06 | 0.48 | 2.32 | 0.88 |
Lymph nodes positive (y/n) (Ref. no) | 1.26 | 0.63 | 2.50 | 0.50 |
CA19-9 > 37 U/mL (y/n) (Ref. yes) | 0.81 | 0.41 | 1.58 | 0.54 |
Surgery (y/n) (Ref. no) | 0.40 | 0.17 | 0.96 | 0.04 |
